Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer.
Adult
Alphapapillomavirus
/ genetics
Biomarkers, Tumor
/ metabolism
Case-Control Studies
Cell Line, Tumor
Cervix Uteri
/ pathology
Circulating MicroRNA
/ metabolism
DNA, Viral
/ urine
Early Detection of Cancer
/ methods
Female
Gene Expression Profiling
Healthy Volunteers
Humans
Kaplan-Meier Estimate
Liquid Biopsy
/ methods
Male
MicroRNAs
/ metabolism
Papillomavirus Infections
/ diagnosis
Prevalence
Prognosis
Prospective Studies
Uterine Cervical Neoplasms
/ diagnosis
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 05 2021
14 05 2021
Historique:
received:
25
11
2020
accepted:
23
04
2021
entrez:
15
5
2021
pubmed:
16
5
2021
medline:
30
10
2021
Statut:
epublish
Résumé
MicroRNAs as cancer biomarkers in serum, plasma, and other body fluids are often used but analysis of miRNA in urine is limited. We investigated the expression of selected miRNAs in the paired urine, serum, cervical scrape, and tumor tissue specimens from the women with cervical precancer and cancer with a view to identify if urine miRNAs could be used as reliable non-invasive biomarkers for an early diagnosis and prognosis of cervical cancer. Expression of three oncomiRs (miR-21, miR-199a, and miR-155-5p) and three tumor suppressors (miR-34a, miR-145, and miR-218) as selected by database search in cervical pre-cancer, cancer, and normal controls including cervical cancer cell lines were analyzed using qRT-PCR. The expression of miRNAs was correlated with various clinicopathological parameters, including HPV infection and survival outcome. We observed a significant overexpression of the oncomiRs and the downregulation of tumor suppressor miRNAs. A combination of miR-145-5p, miR-218-5p, and miR-34a-5p in urine yielded 100% sensitivity and 92.8% specificity in distinguishing precancer and cancer patients from healthy controls and it well correlates with those of serum and tumor tissues. The expression of miR-34a-5p and miR-218-5p were found to be independent prognostic factors for the overall survival of cervical cancer patients. We conclude that the evaluation of the above specific miRNA expression in non-invasive urine samples may serve as a reliable biomarker for early detection and prognosis of cervical cancer.
Identifiants
pubmed: 33990639
doi: 10.1038/s41598-021-89388-w
pii: 10.1038/s41598-021-89388-w
pmc: PMC8121812
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating MicroRNA
0
DNA, Viral
0
MIRN218 microRNA, human
0
MIRN34 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
10323Références
Br J Cancer. 2012 Apr 24;106(9):1526-34
pubmed: 22472886
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9136-41
pubmed: 16754881
Biomark Med. 2015;9(2):131-51
pubmed: 25689901
Viruses. 2015 Aug 19;7(8):4734-55
pubmed: 26295406
Oncol Rep. 2016 Jan;35(1):3-12
pubmed: 26530778
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):553-60
pubmed: 23549399
Princess Takamatsu Symp. 1991;22:239-48
pubmed: 1668886
Tumour Biol. 2014 Dec;35(12):11933-8
pubmed: 25155037
Carcinogenesis. 2010 Jun;31(6):1037-44
pubmed: 20351093
Biochim Biophys Acta. 2009 Jun;1792(6):497-505
pubmed: 19268705
Mol Clin Oncol. 2016 Jul;5(1):189-194
pubmed: 27330796
J Clin Virol. 2006 Nov;37(3):190-4
pubmed: 16931139
Int J Mol Med. 2019 Jul;44(1):185-195
pubmed: 31059001
Int J Oncol. 2012 Dec;41(6):1897-912
pubmed: 23026890
Nucleic Acids Res. 2013 Jul;41(Web Server issue):W169-73
pubmed: 23680784
EBioMedicine. 2019 Dec;50:135-143
pubmed: 31780396
Int J Gynaecol Obstet. 2005 Sep;90(3):223-7
pubmed: 16043176
World J Surg Oncol. 2018 Oct 12;16(1):204
pubmed: 30314496
J Natl Cancer Inst. 2008 Apr 2;100(7):513-7
pubmed: 18364507
BMC Cancer. 2013 Jul 03;13:327
pubmed: 23819460
Virol J. 2019 Oct 7;16(1):116
pubmed: 31590680
Mol Cancer. 2015 Jun 09;14:116
pubmed: 26051842
J Virol. 2013 May;87(10):6037-43
pubmed: 23468503
Eur Rev Med Pharmacol Sci. 2016 Dec;20(23):4846-4851
pubmed: 27981553
Front Oncol. 2020 Feb 20;10:150
pubmed: 32154165
BMC Cancer. 2017 Sep 21;17(1):658
pubmed: 28934937
Mol Med Rep. 2015 Jul;12(1):55-62
pubmed: 25695263
Recent Results Cancer Res. 2014;193:135-48
pubmed: 24008297
Arch Gynecol Obstet. 2018 Feb;297(2):433-442
pubmed: 29177591
Biomed Pharmacother. 2018 Jan;97:511-517
pubmed: 29091902
Arch Virol. 2014 Feb;159(2):199-205
pubmed: 24022639
Bioinformatics. 2020 Apr 15;36(8):2628-2629
pubmed: 31882993
PLoS One. 2015 May 26;10(5):e0127109
pubmed: 26010154
J Cancer Educ. 2015 Mar;30(1):130-7
pubmed: 25355525
RNA. 2008 Jun;14(6):1012-7
pubmed: 18426918
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Can J Kidney Health Dis. 2017 May 22;4:2054358117705371
pubmed: 28616250
PLoS One. 2013;8(1):e53597
pubmed: 23301094
Biosci Rep. 2019 Mar 15;39(3):
pubmed: 30833362
Cancer Sci. 2007 Oct;98(10):1505-11
pubmed: 17645777
Rev Med Virol. 2009 Mar;19(2):97-113
pubmed: 19156753
Mol Clin Oncol. 2015 Jul;3(4):851-858
pubmed: 26171195
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Bioinforma. 2013 Sep 28;3(1):17
pubmed: 24073882
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Lancet. 1992 Dec 5;340(8832):1417-8
pubmed: 1360129
Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):10655-60
pubmed: 27601638
Biomed Res Int. 2020 Mar 23;2020:4947381
pubmed: 32280688
Biomark Med. 2013 Aug;7(4):623-31
pubmed: 23905899
PLoS One. 2016 Jul 12;11(7):e0158946
pubmed: 27404381
Oncol Rep. 2019 Apr;41(4):2209-2225
pubmed: 30816541